LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Отворен

СекторЗдравеопазване

3.95 1.28

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.77

Максимум

3.99

Ключови измерители
By Trading Economics
Приходи	3.4M -9.8M
Служители	34
EBITDA	3.5M -9.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+359.77% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	124M 389M
Предишно отваряне	2.67
Предишно затваряне	3.95

Настроения в новините

By Acuity

29%

71%

60 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.02.2026 г., 23:47 ч. UTC

Горещи акции

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11.02.2026 г., 22:59 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Grab Holdings to Buy U.S.-Based Stash Financial

11.02.2026 г., 23:54 ч. UTC

Печалби

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11.02.2026 г., 23:49 ч. UTC

Печалби

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11.02.2026 г., 23:45 ч. UTC

Печалби

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11.02.2026 г., 23:42 ч. UTC

Печалби

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11.02.2026 г., 23:41 ч. UTC

Печалби

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11.02.2026 г., 23:40 ч. UTC

Печалби

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11.02.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11.02.2026 г., 23:18 ч. UTC

Пазарно говорене

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11.02.2026 г., 23:14 ч. UTC

Пазарно говорене

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11.02.2026 г., 22:59 ч. UTC

Печалби

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11.02.2026 г., 22:59 ч. UTC

Печалби

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11.02.2026 г., 22:59 ч. UTC

Печалби

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11.02.2026 г., 22:58 ч. UTC

Печалби

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11.02.2026 г., 22:57 ч. UTC

Печалби

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11.02.2026 г., 22:54 ч. UTC

Печалби

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11.02.2026 г., 22:53 ч. UTC

Печалби

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11.02.2026 г., 22:47 ч. UTC

Печалби

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11.02.2026 г., 22:47 ч. UTC

Печалби

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11.02.2026 г., 22:23 ч. UTC

Печалби

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11.02.2026 г., 22:22 ч. UTC

Печалби

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11.02.2026 г., 22:22 ч. UTC

Печалби

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11.02.2026 г., 22:19 ч. UTC

Печалби

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11.02.2026 г., 22:18 ч. UTC

Печалби

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11.02.2026 г., 22:18 ч. UTC

Печалби

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11.02.2026 г., 22:18 ч. UTC

Печалби

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11.02.2026 г., 22:16 ч. UTC

Печалби

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

359.77% нагоре

12-месечна прогноза

Среден 20 USD 359.77%

Висок 20 USD

Нисък 20 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

60 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.